Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gadolinium-chelated polysiloxane based nanoparticle - NH TherAguix

Drug Profile

Gadolinium-chelated polysiloxane based nanoparticle - NH TherAguix

Alternative Names: Activation and Guidance of Irradiation X (AGuIX); AGuIX; AGuIX Gadolinium-based Nanoparticles; AGuIX® nanoparticles; Gadolinium-chelated polysiloxane based nanoparticle-NH TherAguix

Latest Information Update: 03 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NH TherAguix
  • Class Antineoplastics; Gadolinium-containing contrast agents; Imaging agents; Radiation-sensitising agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Brain metastases; Cancer; Glioblastoma
  • Phase I/II Non-small cell lung cancer; Pancreatic cancer
  • Phase I Cervical cancer

Most Recent Events

  • 03 Jan 2024 NH TherAguix plans a phase II trial in Glioblastoma, in European Union (NH TherAguix pipeline, January 2024)
  • 03 Jan 2024 NH TherAguix plans a phase II trial in Pancreatic cancer and Non small cell lung cancer in USA (NH TherAguix pipeline, January 2024)
  • 06 Apr 2023 Phase-I development is ongoing France
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top